Enliven Therapeutics
ELVN
102 hedge funds and large institutions have $1.22B invested in Enliven Therapeutics in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 42 increasing their positions, 23 reducing their positions, and 10 closing their positions.
90% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 10
83% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 23
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
10% more funds holding
Funds holding: 93 → 102 (+9)
8% more capital invested
Capital invested by funds: $1.13B → $1.22B (+$88.8M)
1.77% less ownership
Funds ownership: 102.72% → 100.95% (-1.8%)
77% less call options, than puts
Call options by funds: $3K | Put options by funds: $13K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.9M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$7.44M |
| 3 |
Janus Henderson Group
London,
|
+$7.25M |
| 4 |
ABG
Ally Bridge Group
New York
|
+$5.44M |
| 5 |
BlackRock
New York
|
+$4.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$24.6M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
-$19.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$13.3M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$12.3M |
| 5 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$3.56M |
ELVN Hedge Fund Activity: Q3 2024 in Review
102 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q3 2024, worth a combined $1.22B — up 7.9% from $1.13B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ELVN positions and 10 closed out — a net gain of 9 holders — while 42 added to existing stakes and 23 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $13.9M. The largest seller was RA Capital Management, cutting an estimated $24.6M.
- 102 institutional investors held Enliven Therapeutics (ELVN) as of Q3 2024, up from 93 in Q2 2024.
- Funds reported $1.22B of Enliven Therapeutics stock for Q3 2024, up 7.9% quarter-over-quarter.
- 19 funds opened new Enliven Therapeutics positions in Q3 2024 and 10 closed out, a net change of +9 holders.
- The largest Enliven Therapeutics buyer in Q3 2024 was Fidelity Investments, an estimated $13.9M added.
- The largest Enliven Therapeutics seller in Q3 2024 was RA Capital Management, an estimated $24.6M sold.
Based on aggregated 13F filings for Q3 2024.